Thyroid eye disease
Oct 20, 2026
Nouscom Announces €120 Million Series D Funding and Upcoming Presentation of Long-Term Lynch Syndrome Clinical Data at ESMO; Viatris Announces FDA Approval of RYZUMVI for Presbyopia; Lilly’s Omvoh Meets Clinical Remission Endpoint in Children with Ulcerative Colitis; Estuary Biotherapeutics Debuts with $103 Million in Funding to Tackle Kidney Disease; Roche’s Enspryng Receives FDA Approval as a First-in-Class IL-6R Inhibitor for Thyroid Eye Disease
Nouscom Secures Major Series D Funding and Prepares to Share Long-Term Clinical Findings in Lynch Syndrome Carriers at ESMO Nouscom has announced the completion of an oversubscribed €120 million ($135 million) Series D financing round. The investment was co-led by M Ventures and Revelation Partners, with partici...
Read More...
Oct 13, 2026
Efzimfotase Alfa Achieves 17.05-Metre Numerical Improvement Over Placebo in Six-Minute Walk Test; Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Study of AIC468 for BK Virus; Teva’s WELTRUZA Gains FDA Approval for Once-Monthly Treatment of Adult Schizophrenia; Innovent’s SYCUME Meets Primary Endpoint in Phase 3 Inactive Thyroid Eye Disease Trial; Zealand Pharma’s Petrelintide Delivers Positive Topline Results in Phase 2 ZUPREME-2 Trial
Efzimfotase Alfa Shows Numerical Improvement in Six-Minute Walk Distance Versus Placebo in HICKORY Phase III Trial Results from the HICKORY Phase III trial indicated that efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy, did not achieve statistical significance for the primary endpoint ...
Read More...
Jun 30, 2026
Zymeworks Announces Acquisition of Theravance Biopharma; Ipsen to Acquire Kartos Therapeutics; Viridian Therapeutics Wins U.S. FDA Approval for Lumvoa; Replimune Reaches FDA Milestone with RP1 BLA Resubmission Acceptance; Epicrispr Announces Encouraging Clinical Data for EPI-321 in FSHD
Zymeworks Signs Definitive Agreement to Acquire Theravance Biopharma Zymeworks Inc. has signed a definitive agreement to acquire Theravance Biopharma, Inc., marking a strategic step in expanding its commercial portfolio. The acquisition will bring YUPELRI®, the first and only once-daily nebulized long-acting mus...
Read More...
Dec 16, 2025
Pilatus Biosciences Advances PLT012 Into the Clinic Following FDA IND Clearance; ENHERTU + pertuzumab Receives US Approval as the First New First-line Option in a Decade for HER2-positive Metastatic Breast Cancer; Sanofi Reports on Tolebrutinib Development in Primary Progressive MS; Gilead Reports Positive Phase 3 Results for Bictegravir–Lenacapavir Investigational HIV Therapy; argenx Announces Study Update for UplighTED Program of Efgartigimod SC in Thyroid Eye Disease
Pilatus Biosciences Receives FDA IND Clearance for PLT012, a Novel Anti-CD36 Metabolic Checkpoint Antibody Pilatus Biosciences has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PLT012, a first-in-class, humanized anti-CD36 monoclonal ant...
Read More...
Jan 24, 2025
Graves’ Disease Drug Pipeline: 6 Late-Stage Therapies to Watch
The pipeline for Graves’ disease drug treatments is rapidly expanding, with prominent companies such as Immunovant, Viridian Therapeutics, Argenx, Tourmaline Bio, Hoffmann-La Roche, and Sling Therapeutics spearheading the development of targeted therapies for thyroid disorders. Promising candidates in the late stag...
Read More...
Jan 20, 2025
Thyroid Eye Disease: The Hidden Impact of Thyroid Dysfunction on Eye Health
Thyroid eye disease is a rare but serious autoimmune condition that affects the eyes, often linked to hyperthyroidism or Graves’ disease. Around 25-50% of people with Graves’ disease develop TED, with women being more commonly affected than men. There were 1.4 million diagnosed prevalent cases of TED in 20...
Read More...
Jan 17, 2025
Graves’ Disease Treatment Revolution: What’s Next in Line?
Affecting around 1 in 200 people, Graves’ disease is the most common cause of an overactive thyroid. More than 12% of the US population will develop a thyroid condition during their lifetime and an estimated 20 million Americans have some form of thyroid disease. As per DelveInsight’s estimates, Graves’ disease...
Read More...
Jul 29, 2024
Late-Stage Thyroid Eye Disease Treatments: 4 Prominent Therapies to Consider
With an estimated 1 million patients affected in the US, thyroid eye disease is a burden for some disorders which become sight-threatening in upto 5% of the cases. Until today, only one thyroid eye disease treatment drug for adults has been approved by the FDA. Developed by Horizon Therapeutics (now acquir...
Read More...
Feb 20, 2024
FDA Approves Xolair for Food Allergies; FDA Accelerated Approval for Iovance’s AMTAGVI; Astellas and Kelonia Enter into Research and License Agreement; Fast Track Designation to Certa’s FT011; Innovent Announces Phase 3 Clinical Trial Updates for IBI311; Orphan Drug Designation to Cardiol’s Pericarditis Drug Candidate
FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies Roche has announced that the FDA has approved Xolair® (omalizumab) to mitigate allergic responses, such as anaphylaxis, that may arise from accidental exposure to various foods in both adult and pediatric patie...
Read More...
May 19, 2023
Graves’ Ophthalmopathy Treatment Market: A Billion-Dollar Opportunity For Pharma Companies
Graves’ ophthalmopathy, also known as thyroid-associated ophthalmopathy and thyroid eye disease, is the most frequent extrathyroidal manifestation of Graves’ disease. The majority of Graves’ ophthalmopathy cases are caused due to Graves’ disease, and only a small percentage of these patients arise from other euthyr...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
